Pulmonary Hypertension Program
Pulmonary Hypertension (PH) is high blood pressure in the arteries connecting the heart and lungs. It is a broad term that applies to any condition that elevates the lung artery pressure.
This abnormally high pressure strains the right ventricle of the heart, causing it to expand in size. Overworked and enlarged, the right ventricle gradually becomes weaker and loses its ability to pump enough blood to the lungs. Pulmonary hypertension occurs in individuals of all ages, races, and ethnic backgrounds, although it is much more common in young adults and is approximately twice as common in women as in men.
The Pulmonary Hypertension Program physicians and nurses have special expertise and interest in pulmonary hypertension, and are dedicated to the evaluation and care of their patients with pulmonary hypertension.
• Pulmonary Arterial Hypertension (PAH)*
• Elevated left atrial pressures
• Intrinsic pulmonary disease (ILD, emphysema, bronchitis)
• Sleep Apnea
*Additionally, an uncommon illness, Pulmonary Artery Hypertension (PAH) is an important cause of PH as new therapies are available. PAH is sometimes associated with infl or collagen vascular diseases such as scleroderma, rheumatoid arthritis, or systemic lupus erythematosus (SLE). Congenital heart disease, liver disease and some diet drugs may cause PAH. If there is no known cause, the term idiopathic PAH is used.
Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. Swelling in the ankles, abdomen or legs, bluish lips and skin, and chest pain may occur as strain on the heart increases. Symptoms range in severity and a given patient may not have all of the symptoms.
For a prompt diagnosis, our program offers all currently available diagnostic and therapeutic testing, including:
• Invasive hemodynamic assessment with vasodilator testing
• Exercise hemodynamic assessments
• Cardiopulmonary exercise testing
Treatment and Education
Our Pulmonary Hypertension team off the experience and expertise that enables us to prescribe all available FDA approved therapies including:
• Multidisciplinary individualized care
• Endothelial receptor antagonists
• PDE-Inhibitors (sildenafi tadalafi
• Protacyclins-oral, inhaled or chronic IV
• FDA sponsored clinical trials may be off
Heart Failure Education and Monitoring
The Pulmonary Hypertension Program is designed to improve quality of life, improve prognosis, decrease hospital stays and prevent hospitalization.